

Decisions by the Board of Directors on Share Capital Measures

Aubagne, July 18, 2014 – Pursuant to the authorization granted by the Annual General Meeting of Shareholders (AGM) in April 2014, the Board of Directors of Sartorius Stedim Biotech S.A. yesterday resolved to cancel 1,698,710 treasury shares representing approx. 10% of the company's total share capital. Once this cancellation has taken place, Sartorius Stedim Biotech S.A. will no longer hold any treasury shares, and the number of issued shares without exercisable options will total 15,359,238.

In order to facilitate the Group's future growth, the AGM had also authorized the Board of Directors to increase the share capital of Sartorius Stedim Biotech S.A. by issuing up to two million new shares. This authorization remains in effect and may be used by the Board of Directors in the future to realize external growth opportunities.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions."

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,300 people, and in 2013 earned sales revenue of 588.4 million euros.

Contact: Petra Kirchhoff; Vice President of Corporate Communications
Sartorius Corporate Administration GmbH, 37070 Goettingen, Germany
Phone: +49(0)551.308.1686; Fax: +49(0)551.308.3410
E-mail: petra.kirchhoff@sartorius.com; www.sartorius-stedim.com